Transformative RNA-Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Genetic Diseases Our innovative RNA-based therapies, based on Antisense Oligonucleotides (ASOs) restore protein functionality, addressing untreatable genetic pulmonary illnesses. TECHNOLOGY PIPELINE Transformative RNA-Based Treatments SpliSense is a company developing transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses. Our treatment […]
Total raised: $28.5M
Investors 1
| Date | Name | Website |
| - | Israel Bio... | ibf.fund |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2021 | Series B | $28.5M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 03.04.2024 | SpliSense Announces FDA Clearance of Investigational New Dru... | – Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additiona... | ibf.fund/n... |
| 03.04.2024 | CF Foundation Provides Up to $8.5M to SpliSense to Support a... | The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotid... | ibf.fund/n... |
| 03.06.2023 | Глубокий вдох для лечения редкого заболевания легких... | 3 июня 2023 г. Прорывная терапия редкой и потенциально смертельной формы заболевания легких заключае... | vc.ru/tech... |
| 13.05.2021 | SpliSense : Secures $28.5 Million in Series B Financing | JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense, a biopharmaceutical company developing transforma... | marketscre... |
| 13.05.2021 | SpliSense Secures $28.5 Million in Series B Financing | Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation pa... | ibf.fund/n... |